Adaptive Biotechnologies (ADPT) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Adaptive Biotechnologies (ADPT) overview

Adaptive Biotechnologies (ADPT) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 277m and operating profit of USD -57.1m; the year-end share price was 16.24 USD and market capitalisation was USD 2,497m. Adaptive Biotechnologies is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Adaptive Biotechnologies's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 219mFY 2025
Share price16.24 USDFY 2025 year end
RevenueUSD 277mFY 2025
Operating profitUSD -57.1mFY 2025
Net earningsUSD -59.5mFY 2025
Market capitalisationUSD 2,497mFY 2025 year end

About Adaptive Biotechnologies

Adaptive Biotechnologies applies immune system sequencing and analysis technologies to develop clinical products and services. Its MRD business offers clonoSEQ testing to clinicians for detecting and monitoring residual disease in lymphoid cancers, and provides the assay to biopharmaceutical partners for drug development. Its Immune Medicine business offers immune receptor sequencing, proprietary data licensing, TCR-antigen prediction models, and target discovery capabilities.

Generate the Adaptive Biotechnologies report

Adaptive Biotechnologies is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Adaptive Biotechnologies and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Adaptive Biotechnologies

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.